Merck absorbs $200 million in tariff costs into its earnings and full-year outlook

Shares of Merck & Co. were headed higher in early Thursday trading, after the drugmaker extended its long streak of quarterly earnings beats and held firm with its full-year outlook despite expected tariff costs.